Translational Genomics in Leukaemia

Despite significant improvements in survival rates over the decades, leukaemia still remains the second cause of cancer-related death in children. Many children with leukaemia continue to have poor prognosis due to treatment-related toxicity, therapy-resistance and relapse, and children with relapsed leukaemia are currently exposed to life-threatening conditions. New treatments are urgently needed to improve long term outcomes for these children. 

Using cutting-edge technologies and innovative strategies, the main research topics of the Translational Genomics in Leukaemia team are to:

1. Dissect the genetic molecular causes of leukaemia initiation and development.
2. Identify the key features of treatment resistance and relapse initiation.
3. Screen thousands of drugs to eradicate leukaemia cells.
4. Develop clinically relevant models of leukaemia to assess efficacy of new therapies and facilitate their rapid translational to the clinic.

Our team collaborates with local, national and international leaders and clinicians to make a tangible difference in improving outcomes for children with leukaemia. .